News
One short article a day about a new publication from an official source: medicines regulators (FDA, EMA), central banks (Federal Reserve, ECB) and the SEC. Every sentence points to the source and is checked against it before publication. No price targets, no recommendations.
- CHMP recommends six new medicines at its October 2026 meeting
- FDA expands Anktiva approval to BCG-unresponsive high-grade papillary-only bladder cancer
- EMA committee recommends authorisation of Rasonque for metastatic pancreatic cancer
- FDA launches Rare Disease Framework Initiative for drug development
- ECB survey: credit terms eased slightly for a fourth consecutive quarter
- ACT EU clinical trial application advice pilot to become permanent from January 2027
Headlines from other publications are listed on each company page. Earlier rewritten news from the first version of the site is in the archive.